Clinical Efficacy of Stem Cell Mediated Osteogenesis and Bioceramics for Bone Tissue Engineering

Advances in Experimental Medicine and Biology

Volumn 760, Issue , 2012, Pages 174-187

  Neman, Josh ^a   Hambrecht, Amanda ^b   Cadry, Cherie ^c   Goodarzi, Amir ^d   Youssefzadeh, Jonathan ^e   Chen, Mike Y ^a   Jandial, Rahul ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone Regeneration; Bone Tissue Engineering; Mesenchymal Stem Cell; Osteogenic Differentiation; Spinal Fusion

Indexed keywords

BIOCERAMICS; BIOMATERIAL;

APOPTOSIS; BONE DEVELOPMENT; BONE TISSUE; BONE TRANSPLANTATION; CELL CONTACT; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; EXTRACELLULAR MATRIX; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPINE FUSION; STEM CELL; TISSUE ENGINEERING; ARTICLE; BONE MINERALIZATION; CERAMICS; INTERVERTEBRAL DISK DEGENERATION; METHODOLOGY; PHYSIOLOGY; REGENERATION; SPINE DISEASE; STEM CELL TRANSPLANTATION;

BIOCOMPATIBLE MATERIALS; CALCIFICATION, PHYSIOLOGIC; CERAMICS; HUMANS; INTERVERTEBRAL DISC DEGENERATION; OSTEOGENESIS; REGENERATION; SPINAL DISEASES; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

EID: 84872768331     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4090-1_11     Document Type: Chapter

References (84)

1. Ciacci l, Ho A Ames CP et al. Stem cell horizons in intervertebral disc degeneration. Stem cells and Cloning: Advances and Applications. 2008; 1:31-39.
2. Sheyn D, Pelled G, Zilberman Y et al. Nonvirally engineered porcine adipose tissue-derived stem cells: use in posterior spinal fusion. Stem Cells 2008; 26(4):1056-1064.
3. Deyo RA, Nachemson A, Mirza SK. Spinal-fusion surgery-the case for restraint. N Engl.I Med 2004; 350(7):722-726.
4. Lee CK, Langrana NA. Lumbosacral spinal fusion. A biomechanical study. Spine (Phila Pa 1976). 1984; 9(6):574-581.
5. Carragee E.I. Clinical practice. Persistent low back pain. N Engl.I Med 2005; 352(18): 1891-1898.
6. Miyazaki M. Tsumura H, Wang JC et al. An update on bone substitutes for spinal fusion. Eur Spine J 2009; 18(6):783-799.
7. Bueno EM. Glowacki 1. Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol 2009; 5(12):685-697.
8. Russell JL. Block JE. Clinical utility of demineralized bone matrix for osseous defects. arthrodesis and reconstruction: impactofprocessingtechniques and study methodology. Drthopedics 1999;22(5):524-531; quiz 532-523.
9. Schwartz Z, Mellonig IT, Cames DL.lr et al. Ability of commercial demineralized freeze-dried bone allograft to induce new bone formation. J Periodontol1996; 67(9):918-926.
10. Yaszemski M, Dldham l, Currier B. Bone Engineering. Toronto: EM Squared Incorporated 2000.
11. Kanczler JM, Dreffo RD. Dsteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 2008; 15:100-114.
12. Kasper G, Dankert N, Tuischer.l et al. Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. Stem Cells 2007; 25(4):903-910.
13. Potier E, Ferreira E, Meunier A et al. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007; 13(6):1325-1331.
14. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World.l Gastroenterol 2003; 9(6):1144-1155.
15. Sundelacruz S, Kaplan DL. Stem cell-and scaffold-based tissue engineering approaches to osteochondral regenerative medicine. Semin Cell Dev Bioi 2009; 20(6):646-655.
16. EI Tamer MK, Reis RL. Progenitor and stem cells for bone and cartilage regeneration..I Tissue Eng Regen Med 2009; 3(5):327-337.
17. Kwan MD, Slater BJ, Wan DC et al. Cell-based therapies for skeletal regenerative medicine. Hum Mol Genet 2008; 17(Rl):R93-R98.
18. Rickard DJ, Sullivan TA, Shenker BJ et al. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev BioI 1994; 161(1):218-228.
19. Jorgensen NR, Henriksen Z, Sorensen OH et al. Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more diflerentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 2004; 69(4):219-226.
20. Hanada K, Dennis JE, Caplan A!. Stimulatory eflects ofbasic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells..I Bone Miner Res 1997; 12(10):1606-1614.
21. Yeh LC, Tsai AD, Lee JC. Osteogenic protein-I (OP-I, BMP-7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12. J Cell Biochem 2002; 87(3):292-304.
22. Gregory CA, Gunn WG, Reyes E et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann NY Acad Sci 2005; 1049:97-106.
23. Yang XB, Bhatnagar RS, Li S et al. Biomimetic collagen scaffolds for human bone cell growth and diflerentiation. Tissue Eng 2004; 10(7-8):1148-1159.
24. Salasznyk RM, Klees RF, Hughlock MK etal. ERK signaling pathways regulate the osteogenic differentiation ofhuman mesenchymal stem cells on collagen I andvitronectin. Cell CommunAdhes 2004; 11( 5-6): 137-153.
25. Salasznyk RM, Williams WA, Boskey A et al. Adhesion to vitronectin and collagen I promotes osteogenic diflerentiation of human mesenchymal stem cells. J Biomed Biotechnol2004; 2004(1):24-34.
26. Murphy WL, Hsiong S, Richardson TP et al. Effects of a bone-like mineral film on phenotype of adult human mesenchymal stem cells in vitro. Biomaterials 2005; 26(3):303-310.
27. Salgado AJ, Figueiredo JE, Coutinho OP et al. Biological response to premineralized starch based scaflolds for bone tissue engineering..I Mater Sci Mater Med 2005; 16(3):267-275.
28. Chamberlain G, FoxJ, AshtonB etal. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25(11):2739-2749.
29. Fox JM, Chamberlain G, Ashton BA et al. Recent advances into the understanding of mesenchymal stem cell trafficking. BrJ Haematol2007; 137(6):491-502.
30. Deschaseaux F, Sensebe L, Heymann D. Mechanisms of bone repair and regeneration. Trends Mol Med 2009; 15(9):417-429.
31. Gerstenfeld LC, Cullinane DM, Barnes GL et al. Fracture healing as a postnatal developmental process: molecular, spatial and temporal aspects of its regulation..I Cell Biochem 2003;88(5):873-884.
32. Dimitriou R, Tsiridis E, Giannoudis PY. Current concepts of molecular aspects of bone healing. Injury 2005; 36(12):1392-1404.
33. Einhorn TA, Majeska RJ, Rush EB et al. The expression of cytokine activity by fracture callus. J Bone Miner Res 1995; 10(8):1272-1281.
34. Kon T, Cho TJ, Aizawa T et al. Expression of osteoprotegerin, receptor activator ofNF-kappaB ligand (osteoprotegerin ligand) and related proinfiammatory cytokines during fracture healing..I Bone Miner Res 2001; 16(6):1004-1014.
35. Balga R, Wetterwald A, Portenier I et al. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Bone 2006; 39(2):325-335.
36. Li X, Wang H, Touma E et al. TP508 accelerates fracture repair by promoting cell growth over cell death. Biochem Biophys Res Commun 2007; 364(1):187-193.
37. Aspenberg P. Drugs and fracture repair. Acta Orthop 2005; 76(6):741-748.
38. Paralkar VM, Borovecki F, Ke HZ et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 2003; 100(11):6736-6740.
39. Chen Y, Whetstone HC, Youn A et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation..I BioI Chern 5 2007; 282(1):526-533.
40. Ebisawa T, Tada K, Kitajima I et al. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation..I Cell Sci 1999; 112(Pt 20):3519-3527.
41. Cheng H, Jiang W, Phillips FM et al. Osteogenic activity ofthe fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003; 85-A(8):1544-1552.
42. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 1998; 22( 6):591-603.
43. Cho TJ, Gerstenfeld LC, Einhorn TA. Diflerential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing..I Bone Miner Res 2002; 17(3):513-520.
44. Bostrom MP, Lane JM, Berberian WS et al. Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing..I Orthop Res 1995; 13(3):357-367.
45. Jane JA, Jr., Dunford BA et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 2002; 6(4):464-470.
46. Kilian KA, Bugarija B, Lahn BT, et al. Geometric cues for directing the diflerentiation of mesenchymal stem cells. Proc Nat! Acad Sci USA 2010; 107(11):4872-4877.
47. Hens JR, Wilson KM, Dann P et al. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 2005; 20(7): II 03-1113.
48. Robinson JA, Chatterjee-Kjshore M, Yaworsky PJ etal. Wntlbeta-catenin signaling is a normal physiological response to mechanical loading in bone. J Bioi Chern 2006; 281 (42):31720-31728.
49. Lee JY, Marston DJ, Walston T et al. WntlFrizzled signaling controls C. elegans gastrulation by activating actomyosin contractility. Curr Bioi 2006; 16(20): 1986-1997.
50. Wozniak MA, Chen CS. Mechanotransduction in development: a growing role for contractility. Nat Rev Mol Cell Bioi 2009; 10(1):34-43.
51. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Bioi 2006; 16(3):151-158.
52. Day TF, Guo X, Garrett-Beal L et al. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte diflerentiation during vertebrate skeletogenesis. Dev Cell. 2005; 8(5):739-750.
53. Hill TP, Spater D, Taketo MM et al. Canonical Wntlbeta-catenin signaling prevents osteoblasts from diflerentiating into chondrocytes. Dev Cell 2005;8(5):727-738.
54. Bennett CN, Longo KA, Wright WS et al. Regulation of osteoblastogenesis and bone mass by Wntl 0b. Proc Nat! Acad Sci USA. 2005; 102(9):3324-3329.
55. Clement-Lacroix P, Ai M, Morvan F et al. Lrp5-independent activation ofWnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Nat! Acad Sci USA 2005; 102(48): 17406-17411.
56. Delecrin J, Takahashi S, Gouin F, et al. A synthetic porous ceramic as a bone graft substitute in the surgical management of scoliosis: a prospective, randomized study. Spine (Phila Pa 1976).2000; 25(5):563-569.
57. Evaluation criteria for musculoskeletal and craniofacial tissue engineering constructs: a conference report. Tissue Eng Part A 2008; 14(12):2089-2104.
58. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008; 2(2-3):81-96.
59. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaflolds and osteogenesis. Biomaterials 2005; 26(27):5474-5491.
60. Roy TD, Simon JL, Ricci JL et al. Performance of degradable composite bone repair products made via three-dimensional fabrication techniques. J Biomed Mater Res A 2003;66(2):283-291.
61. Richards M, Huibregtse BA, Caplan AI et al. Marrow-derived progenitor cell injections enhance new bone formation during distraction. J Orthop Res 1999; 17(6):900-908.
62. Cancedda R, Dozin B, Giannoni P et al. Tissue engineering and cell therapy of cartilage and bone. Matrix Bioi 2003; 22(1):81-91.
63. Braunecker J, Baba M, Milroy GE et al. The eflects of molecular weight and porosity on the degradation and drug release from polyglycolide. Int J Pharm 2004; 282( 1-2): 19-34.
64. Thomson RC, Yaszemski MJ, Powers JM et al. Fabrication of biodegradable polymer scaffolds to engineer trabecular bone. J Biomater Sci Polym Ed 1995; 7(1):23-38.
65. Oonishi H, Hench LL, Wilson J et al. Quantitative comparison of bone growth behavior in granules of Bioglass, A-W glass-ceramic and hydroxyapatite. J Biomed Mater Res 2000; 51(1):37-46.
66. Khan Y, Yaszemski MJ, Mikos AG et al. Tissue engineering of bone: material and matrix considerations. J Bone Joint Surg Am 2008; 90 Suppl 1:36-42.
67. TemenofI JS, Lu, L., Mikos, A.G. Bone Engineering. Toronto: EM Squared Incorporated 2000.
68. Mikos AG, Sarakinos G, Lyman MD etal. Prevascularizationofporous biodegradable polymers. Biotechnol Bioeng 1993; 42(6):716-723.
69. Peng H, Usas A, Olshanski A et al. VEGF improves, whereas sFIt! inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Miner Res 2005; 20(11):2017-2027.
70. Geiger F, Bertram H, Berger I etal. Vascular endothelial growth factor gene-activated matrix (VEG F165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 2005; 20( II ):2028-2035.
71. Ortega N, Behonick DJ, Werb Z. Matrix remodeling during endochondral ossification. Trends Cell BioI 2004; 14(2):86-93.
72. Park KH, Kim H, Moon S et al. Bone morphogenic protein-2 (BMP-2) loaded nanoparticles mixed with human mesenchymal stem cell in fibrin hydrogel for bone tissue engineering. J Biosci Bioeng 2009; 108(6):530-537.
73. Hernigou P, Poignard A, Manicom O, et al. The use ofpercutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br 2005; 87(7):896-902.
74. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411):143-147.
75. Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344(5):385-386.
76. Marcacci M, Kon E, Moukbachev V et al. Stem cells associated with macroporous bioceramics for long bone repair: 6-to 7-year outcome ofa pilot clinical study. Tissue Eng 2007; 13(5):947-955.
77. Papachroni KK, Karatzas ON, Papavassiliou KA et al. Mechanotransduction in osteoblast regulation and bone disease. Trends Mol Med 2009; 15(5):208-216.
78. Warnke PH, Wiltfang.l, Springer I etal. Man as living bioreactor: fate ofan exogenously prepared customized tissue-engineered mandible. Biomaterials 2006; 27(17):3163-3167.
79. Vacanti CA, Bonassar LJ, Vacanti MP et al. Replacement of an avulsed phalanx with tissue-engineered bone. N Engl J Med 2001; 344(20):1511-1514.
80. Ueda M, Yamada Y, Kagami H et al. Injectable bone applied for ridge augmentation and dental implant placement: human progress study. Implant Dent 2008; 17(1):82-90.
81. Tolar L, Nauta A.I, Osborn M.I et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25(2):371-379.
82. Tasso R, Augello A, Carida M et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaflolds. Carcinogenesis 2009; 30(1):150-157.
83. Betz VM, Betz OB, Harris MB et al. Bone tissue engineering and repair by gene therapy. Front Biosci 2008; 13:833-841.
84. Gersbach CA, Phillips JE, Garcia AJ. Genetic engineering for skeletal regenerative medicine. Annu Rev Biomed Eng 2007; 9:87-119.